NCT03389126View on ClinicalTrials.gov

Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

December 31, 2019

Study Completion Date

January 31, 2020

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Avelumab

Avelumab 10 mg/kg intravenous injection every 2 weeks until disease progression or unacceptable toxicity

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

Seoul National University Hospital

OTHER

NCT03389126 - Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment | Biotech Hunter | Biotech Hunter